Guggenheim raised the firm’s price target on Bruker (BRKR) to $58 from $53 and keeps a Buy rating on the shares. The firm adjusted models, forecasts and targets for a number of its Diagnostics and Life Sciences Tools covered companies to reflect recent updates and selected pre-announcements of preliminary results last week.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Bruker price target raised to $53 from $40 at Citi
- Bruker: Solid Q4 Momentum and Reaffirmed 2026 Targets Underpin Buy Rating and Upside Potential
- Bruker clarifies regulatory filing status in recent 8-K
- Bruker sees Q4 preliminary revenue $965M-$970M, consensus $958.3M
- Bruker sees 2026 organic revenue growth of flat to up low-single digits